HKeyBio is building HKEY-AI4AI-Atlas™ 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capability-building initiative uses AI-assisted dataset curation, standardization and retrieval to ...
HKeyBio is building HKEY-AI4AI-Atlastm 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capability-building initiative uses AI-assisted dataset curation, standardization and retrieval to ...
Pharmacodynamic effects in the human brain and energy metabolism biomarker data presented at AAIC support further clinical development of VNA-318 ...
People living with early Alzheimer’s disease can now begin treatment with Leqembi without setting foot in an infusion center.
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell ...
NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, will be presenting data from its recently completed Phase 2a clinical trial in ...
Researchers identify the antibiotic concentration where bacteria may be most likely to develop dangerous drug resistance.
HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design BOSTON and SUZHOU, China, July 13, 2026 /PRNewswire/ -- ...
As patients with cystic fibrosis age, their infections become increasingly resistant to treatment, which can threaten their ...
Forte Biosciences offers upside as FB102 demonstrates efficacy in celiac disease and vitiligo, suggesting platform potential ...
The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs ...
UB researcher Nicholas Smith joins Stanford’s NIH-funded Center for Phage Pharmaceuticals to study phage therapy for ...